These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 7589764)

  • 1. Comparison of the efficacy and safety of daily dosages of 6 mg and 20 mg dihydroergocristine in the treatment of chronic cerebro-vascular disease.
    Pagliano FM; Galbiati GC
    J Int Med Res; 1995; 23(4):219-27. PubMed ID: 7589764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dihydroergocristine in the treatment of organic brain psychosyndrome. Dose-finding study against placebo].
    Milvio C
    Arzneimittelforschung; 1992 Nov; 42(11A):1399-402. PubMed ID: 1492861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Controlled clinical study of use of dihydroergocristine in cerebral and periferal vascular disorders].
    Calisti G; Biscarini L; Miseo A
    Clin Ter; 1977 Nov; 83(4):371-86. PubMed ID: 414875
    [No Abstract]   [Full Text] [Related]  

  • 4. [Controlled study of the effect of dihydroergocristine on organic brain psychosyndrome].
    Aranda B; Dumoulin P; Groothold G
    Arzneimittelforschung; 1992 Nov; 42(11A):1406-9. PubMed ID: 1492863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multidimensional approach to the assessment of clinical validity in a study on CCVD treatment: dihydroergocristine versus placebo.
    Fioravanti M; Buckley AE; Agnoli A
    Arch Gerontol Geriatr; 1987 Apr; 6(1):83-93. PubMed ID: 3109340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [One-year therapy with dihydroergocristine for treatment of impaired alertness and memory in elderly patients. Placebo-controlled multicenter study].
    Agliati G; Lazzaroni M; Mariani G; Marras F; Massetto N; Menozzi C; Ortenzi E; Perna G; Puppo N; Santambrogio S
    Arzneimittelforschung; 1992 Nov; 42(11A):1414-6. PubMed ID: 1492865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effect of pharmacological treatment in the compensation of vertigo].
    Pons Rocher F
    An Otorrinolaringol Ibero Am; 1999; 26(3):271-91. PubMed ID: 10394686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dihydroergocristine in organic brain psychosyndrome. Multicenter placebo-controlled clinical double-blind study in 240 patients].
    Lazzaroni M; Cattalini C; Massetto N; Poli A
    Arzneimittelforschung; 1992 Nov; 42(11A):1410-3. PubMed ID: 1492864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydroergocristine in stopping lactation: double-blind study vs bromocriptine.
    de Aloysio D; Pamparana F; Zanotti A; Fabiani AG; Bottiglioni F
    Gynecol Endocrinol; 1988 Mar; 2(1):67-71. PubMed ID: 3140592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Controlled double-blind study of the clinical equivalent of two posologic regimens of Hydergine: 1 x 4,5mg compared to 3 x 1,5mg per day].
    Piguet PV; Zoufal Z
    Rev Med Suisse Romande; 1981 Feb; 101(2):157-63. PubMed ID: 7015453
    [No Abstract]   [Full Text] [Related]  

  • 11. [Therapeutic effectiveness and safety of dihydroergocristine. A study of 9,702 patients].
    Mailland F; Zottino G
    Fortschr Med; 1986 Mar; 104(11):239-42. PubMed ID: 3084366
    [No Abstract]   [Full Text] [Related]  

  • 12. A dose-response study with dihydroergotoxine mesylate in cerebrovascular disturbances.
    Yoshikawa M; Hirai S; Aizawa T; Kuroiwa Y; Goto F; Sofue I; Toyokura Y; Yamamura H; Iwasaki Y
    J Am Geriatr Soc; 1983 Jan; 31(1):1-7. PubMed ID: 6336765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical trials with dihydroergocristine in patients with vascular and cerebral insufficiency].
    Ingelmo M; Vivancos J; Peri J; Balcells Gorina A
    Rev Clin Esp; 1980 Dec; 159(6):399-402. PubMed ID: 6784197
    [No Abstract]   [Full Text] [Related]  

  • 14. [Epidemiologic study on the effectiveness and safety of dihydroergocristine in impaired memory and behavioral functions in aged humans].
    Abate G; Angeleri F; Bartorelli L; Battistin L; Bergamasco B; Bertolini S; Bulfoni A; Capurso A; Cazzato G; Coccagna G
    Arzneimittelforschung; 1992 Nov; 42(11A):1417-21. PubMed ID: 1492866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term treatment of cerebrovascular changes in the elderly (author's transl)].
    Kugler J; Oswald WD; Herzfeld U; Seus R; Pingel J; Welzel D
    Dtsch Med Wochenschr; 1978 Mar; 103(11):456-62. PubMed ID: 631030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memory improvements and pharmacological treatment: a method to distinguish direct effects on memory from secondary effects due to attention improvement.
    Fioravanti M; Di Cesare F
    Int Psychogeriatr; 1992; 4(1):119-26. PubMed ID: 1391667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alcohol-induced organic cerebral psychosyndromes: partial reversal of cognitive impairments assisted by dihydroergocristine.
    Rainer M; Mucke HA; Chwatal K; Havelec L
    Psychopharmacology (Berl); 1996 Oct; 127(4):365-9. PubMed ID: 8923573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hypertension therapy with Briserin: what role do dihydroergocristine components play?].
    Schardt F; Polzien P
    Med Klin; 1981 Dec; 76(26):746-52. PubMed ID: 6798382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of peripheral vascular diseases with dihydroergocristine].
    Moracchini PV; Alfano G; Melandri F
    Minerva Cardioangiol; 1978 Apr; 26(4):277-90. PubMed ID: 97601
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical experiences with the vascular action of dihydroergocristine].
    Tomasi AM; Baggioni GF; Pozzar C
    Minerva Cardioangiol; 1975 Jan; 23(1):7-19. PubMed ID: 806854
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.